Table 3.
Pathological characteristics of the high-grade ductal carcinoma in situ (DCIS) cases (78 cases) according to the presence or absence of associated invasive carcinoma (invasive breast carcinoma).
| Variable | Group 1 (pure DCIS) | Group 2 (DCIS+IBC) | Total | p-value | OR (95% CI) | |
| n | 27 | 51 | 78 | |||
| ER/PR | Positive | 14 (51.8%) | 15 (29.4%) | 29 | 0.05 | 0.38 (0.14–1.01) |
| Negative | 13 (48.2%) | 36 (70.6%) | 49 | |||
| HER2 | Positive (3+) | 18 (66.7%) | 20 (39.2%) | 38 | 0.02 | 0.32 (0.12–0.86) |
| Negative (0/1+) | 9 (33.3%) | 31 (60.8%) | 40 | |||
| Molecular profile | Luminal (A+B) | 5 (27.8%) | 13 (25.5%) | 18 | 0.003 | – |
| Triple-positive | 9 (33.3%) | 2 (3.9%) | 11 | |||
| HER2 | 9 (33.3%) | 18 (35.3%) | 27 | |||
| Triple-negative | 4 (14.8%) | 18 (35.3%) | 22 | |||
| CK 5/6 | Positive | 9/26 (34.6%) | 8/47 (17%) | 17 | 0.09 | 0.38 (0.13–1.17) |
| Negative | 17/26 (65.4%) | 39/47 (83%) | 56 | |||
| EGFR | Positive | 7 (25.9%) | 13/40 (32.5%) | 20 | 0.56 | 1.37 (0.46–4.07) |
| Negative | 20 (74.1%) | 27/40 (67.5%) | 47 |
ER: estrogen receptor; PR: progesterone receptor; HER2: human epidermal growth factor 2; CK 5/6: cytokeratin 5/6; EGFR: epidermal growth factor receptor (human epidermal growth factor 1).